ライフサイエンスコーパス: sipuleucel-T

1 impact and low toxicity are associated with sipuleucel-T.

2 utic armamentarium including cabazitaxel and sipuleucel-T.

3 tigen were observed in patients who received sipuleucel-T.

4 al benefits from immune-based treatment with sipuleucel-T.

5 12 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) ad

6 Finally, sipuleucel-T, a form of immunotherapy, may benefit a sub

7 Radium-223 and sipuleucel-T also are options.

8 The current analysis examined whether sipuleucel-T altered adaptive T-cell responses by expand

9 Sipuleucel-T, an autologous active cellular immunotherap

10 Sipuleucel-T, an autologous dendritic cell based vaccine

11 A pivotal phase III study using Sipuleucel-T, an autologous prostatic acid phosphatase (

12 ple of prostate cancer subjects who received sipuleucel-T, an FDA-approved immunotherapy, we were abl

13 Median survival was 25.9 months for sipuleucel-T and 21.4 months for placebo (P = .01, log-r

14 es include randomized controlled trials with sipuleucel-T and another with PROSTVAC-VF, both of which

15 Cabazitaxel, sipuleucel-T and denosumab were approved in 2010 by regu

16 ll centers and payers ranged between 118.4% (sipuleucel-T) and 633.6% (leuprolide).

17 Sipuleucel-T (APC8015) is an investigational immunothera

18 disease, development of novel immunotherapy (Sipuleucel T), chemotherapy (docetaxel and cabazitaxel),

19 The licensing of ipilimumab and sipuleucel-T for cancer, and the remarkable success of i

20 ent Food and Drug Administration approval of sipuleucel-T for metastatic castration-resistant prostat

21 ts that were more frequently reported in the sipuleucel-T group than in the placebo group included ch

22 -month survival probability was 31.7% in the sipuleucel-T group versus 23.0% in the placebo group.

23 ement in median survival (25.8 months in the sipuleucel-T group vs. 21.7 months in the placebo group)

24 In the sipuleucel-T group, there was a relative reduction of 22

25 erone acetate, enzalutamide, radium-223, and sipuleucel-T has increased the number of treatment optio

26 ide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate ca

27 e-specific membrane antigen [PSMA]-617), and sipuleucel-T have demonstrated an overall survival (OS)

28 taken to evaluate the safety and efficacy of sipuleucel-T in a placebo-controlled study.

29 T FINDINGS: Multiple studies are now testing sipuleucel-T in different disease settings and/or in com

30 Furthermore, sipuleucel-T increased TCR sequence commonality between

31 ial (NCT00715104), we found that neoadjuvant sipuleucel-T increased the number of activated T cells w

32 Sipuleucel-T is an autologous cellular therapy for asymp

33 Sipuleucel-T may be offered to asymptomatic/minimally sy

34 tical significance, this study suggests that sipuleucel-T may provide a survival advantage to asympto

35 Although Sipuleucel-T may receive FDA approval for patients with

36 in a 2:1 ratio to receive three infusions of sipuleucel-T (n = 82) or placebo (n = 45) every 2 weeks.

37 The use of sipuleucel-T prolonged overall survival among men with m

38 approach, with the currently available agent sipuleucel-T providing a significant survival benefit wi

39 Sipuleucel-T therapy was well tolerated.

40 eks to pretreatment was eight-fold higher in sipuleucel-T-treated patients (16.9 v 1.99; P < .001).

41 nce diversity in resected prostate tissue in sipuleucel-T-treated subjects versus tissue of nonsipule

42 quency and diversity thus demonstrating that sipuleucel-T treatment affected TCR repertoire in blood

43 prostate tissue supports the hypothesis that sipuleucel-T treatment facilitates the recruitment of T

44 In contrast, sipuleucel-T treatment reduced circulating TCR sequence

45 Interestingly, sipuleucel-T treatment resulted in greater TCR sequence

46 TCR sequences between tissue and blood after sipuleucel-T treatment supported the hypothesis that tre

47 an for time to disease progression (TTP) for sipuleucel-T was 11.7 weeks compared with 10.0 weeks for

48 ogous antigen-presenting cell immunotherapy, sipuleucel-T, was the first and remains the only US Food